Abstract
This study aimed at analyzing the relationship between the expression of P-gp, MRP, LRP, GST-π and TopoIIα and acquired resistance to cisplatin in lung adenocarcinoma cell line A549. Drug resistance to cisplatin was determined using MTT assays. The expressions of P-gp, MRP, LRP, GST-π and TopoIIα were measured by immunofluorescence, Western blot and RT-PCR. The results showed that there was a significant elevation of IC50 of cisplatin in A549/DDP cells compared to A549 cells (73.95 ± 7.26 versus 7.28 ± 0.74). The expression of P-gp and MRP in A549/DDP cells was approximately 1.5-fold higher than that in A549 cells (61.99±2.63 versus 43.52±1.22 ; 34.11±2.17 versus 22.80±2.31 respectively), whereas TopoIIα expression was about 3-fold lower in A549/DDP cells than that in A549 cells (0.34±0.06 versus 0.92±0.03). In conclusion, acquired resistance to cisplatin was associated with the up-regulation of P-gp and MRP and the down-regulation of TopoIIα in human lung adenocarcinoma cell line A549.
Keywords: Acquired resistance, Cisplatin, GST, LRP, MRP, P-gp, TopoII, Lung cancer, lung adenocarcinoma cell line, immunofluorescence, lung cancer chemotherapy, P-glycoprotein, multidrug-resistance protein, lung resistance-related protein, Glutathione-s-transferase, TopoisomeraseII, glutathione, epipodophyllotoxins, amsacrine, polyclonal antibody, adenocarcinoma cell
Letters in Drug Design & Discovery
Title: Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Volume: 8 Issue: 2
Author(s): Jiarui Wang, Zhongzhou He, Lichuan Zhang, Encheng Li, Qiang Meng, Lijuan Zou, Joseph Molnar and Qi Wang
Affiliation:
Keywords: Acquired resistance, Cisplatin, GST, LRP, MRP, P-gp, TopoII, Lung cancer, lung adenocarcinoma cell line, immunofluorescence, lung cancer chemotherapy, P-glycoprotein, multidrug-resistance protein, lung resistance-related protein, Glutathione-s-transferase, TopoisomeraseII, glutathione, epipodophyllotoxins, amsacrine, polyclonal antibody, adenocarcinoma cell
Abstract: This study aimed at analyzing the relationship between the expression of P-gp, MRP, LRP, GST-π and TopoIIα and acquired resistance to cisplatin in lung adenocarcinoma cell line A549. Drug resistance to cisplatin was determined using MTT assays. The expressions of P-gp, MRP, LRP, GST-π and TopoIIα were measured by immunofluorescence, Western blot and RT-PCR. The results showed that there was a significant elevation of IC50 of cisplatin in A549/DDP cells compared to A549 cells (73.95 ± 7.26 versus 7.28 ± 0.74). The expression of P-gp and MRP in A549/DDP cells was approximately 1.5-fold higher than that in A549 cells (61.99±2.63 versus 43.52±1.22 ; 34.11±2.17 versus 22.80±2.31 respectively), whereas TopoIIα expression was about 3-fold lower in A549/DDP cells than that in A549 cells (0.34±0.06 versus 0.92±0.03). In conclusion, acquired resistance to cisplatin was associated with the up-regulation of P-gp and MRP and the down-regulation of TopoIIα in human lung adenocarcinoma cell line A549.
Export Options
About this article
Cite this article as:
Wang Jiarui, He Zhongzhou, Zhang Lichuan, Li Encheng, Meng Qiang, Zou Lijuan, Molnar Joseph and Wang Qi, Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells, Letters in Drug Design & Discovery 2011; 8 (2) . https://dx.doi.org/10.2174/157018011794183743
DOI https://dx.doi.org/10.2174/157018011794183743 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism of Action of Flavonoids in Prevention of Inflammation- Associated Skin Cancer
Current Medicinal Chemistry Targeting Triglyceride Metabolism for Colorectal Cancer Prevention and Therapy
Current Drug Targets MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Potential Therapeutic Agents from the Red Sea Organisms
Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Risk Factors for the Pap Test Cytological Changes in Iran: A Multicenter Case-Control Study
Current Women`s Health Reviews Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Therapies for Neurological Disease in the Mucopolysaccharidoses
Current Gene Therapy Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells
Medicinal Chemistry The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Role of Cervical Cancer Radiotherapy in the Expression of EGFR and p53 Gene
Current Proteomics Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism